Mehal 3:15 PM 152: LPS-stimulated stellate cells augment acetaminophen-induced hepatocyte injury: Role for IFN-β Chandrashekhar R. Gandhi 3:30 PM 153: Grb2-associated binder 1 docking protein is crucial for mortality in a mouse model of acute liver failure Kunimaro Furuta, Yuichi Yoshida, Takashi Kizu, Satoshi Ogura, Mayumi Egawa, Norihiro Chatani, Mina Hamano,

Hisao Ezaki, Yoshihiro Kamada, Shinichi Kiso, Tetsuo Takehara 3:45 PM 154: Ethanol-inducible Apoptosis inhibitor CYP2E1 potentiates binge alcohol-induced gut leakiness, steatohepatitis and apoptosis Mohamed A. Abdelmegeed, Atrayee Banerjee, Sehwan Jang, Seong-Ho Yoo, Frank Gonzalez, Ali Keshavarzian, Byoung-Joon Song 4:00 PM 155: Deoxycholic Acid Triggers Primary Rat Hepatocyte Apoptosis in a Dose-Dependent Manner by Hampering Caspase-2/NF-κB-associated Activation of MAPK inhibitor miRNA-21 Pedro M. Rodrigues, Marta B. Afonso, Duarte M. Ferreira, Pedro M. Borralho, Cecilia M. Rodrigues, Rui E. Castro 4:15 PM 156: Activation of protein kinase C delta protects against bile acid induced apoptosis by suppression of a pro-apoptotic JNK/BIM pathway Cynthia R. Webster, Mohammed S. Anwer HCV Symposium

Monday, November 4 4:45 – 6:15 PM Hall E/General Session Integrating New Therapies for the Treatment of Chronic Hepatitis C MODERATORS: Michael W. Fried, MD Nancy Reau, MD The positive impact of HCV treatment on morbidity and mortality remains underappreciated, as evidenced by

the recent proposed report of the USPSTF. This program will emphasize the latest data on improved clinical outcomes and also highlight the latest antiviral therapies that continue to increase the rates of sustained virological response. Combined, this clinical information will provide important motivation for healthcare providers to discuss HCV treatment options with their patients. It will also provide them with the knowledge to select the best individual options from a variety of available treatment RAS p21 protein activator 1 options expected to be approved over the next 6-12 months. Learning Objectives: Identify the impact of HCV therapy on morbidity and mortality Describe the foundation for all oral regimens Explain the strengths and limitations of all-oral regimens under investigation Develop a rational approach to choosing treatment regimens as multiple agents become available 4:45 – 5:00 PM Effectiveness of HCV Therapy for Improving Health Outcomes Harry L. Janssen, MD, PhD 5:00 – 5:15 PM Review of Registration Trials of DAAs Norah Terrault, MD 5:15 – 5:30 PM New Phase II Data from All-Oral Regimens Fred Poordad, MD 5:30 – 5:45 PM Responsible Use of New DAAs in 2014 and Beyond David R. Nelson, MD 5:45 – 6:15 PM Panel Discussion Parallel Session Parallel 23: Cholesterol and Bile Acid Metabolism Monday, November 4 4:45 – 6:15 PM Room 150B MODERATORS: Saul J.